Clinical trial
A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy
NCT03956940 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- October 4, 2019
- Completion date
- December 31, 2021
- Enrollment
- 18 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocarcinoma